Peptide Library

FDA-approved

Hormones & metabolism

Lixisenatide

Evidence

FDA approved

Class

GLP-1 receptor agonist

/

Lixisenatide

KEY TAKEAWAY

Lixisenatide is a short-acting GLP-1 receptor agonist based on exendin-4. It was sold as Adlyxin. The FDA approved lixisenatide (Adlyxin) in 2016. The manufacturer discontinued Adlyxin in the United States in 2023, and a combination with insulin glargine (Soliqua) remains available.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

GLP-1 receptor agonist

Approved for

Type 2 diabetes

Key fact

The FDA approved lixisenatide (Adlyxin) in 2016. The manufacturer discontinued Adlyxin in the United States in 2023, and a combination with insulin glargine (Soliqua) remains available.

Route

Daily subcutaneous injection

Evidence strength

FDA approved

What it is

What it is

Lixisenatide is a short-acting GLP-1 receptor agonist based on exendin-4. It was sold as Adlyxin.

How it works

How it works

It activates GLP-1 receptors, which raises insulin release when blood sugar is high and slows stomach emptying.

Regulatory status

Regulatory status

The FDA approved lixisenatide (Adlyxin) in 2016. The manufacturer discontinued Adlyxin in the United States in 2023, and a combination with insulin glargine (Soliqua) remains available.

What it is used for

What it is used for

Type 2 diabetes.

Side effects and risks

Side effects and risks

Nausea, vomiting and diarrhea are common. Pancreatitis is a rare serious risk.

Citations

Citations

U.S. FDA prescribing information for Lixisenatide. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo